Alzheimer’s Disease/Dementia News

In an open-label extension of the CLARITY-AD study, treatment with IV lecanemab was associated with significant improvement in Alzheimer’s disease-related pathology, continuing a positive treatment effect from the randomization phase.

All stages of research on Alzheimer’s disease and related dementias should include increased public and participant involvement so the benefits are seen across diverse populations, according to a position paper in Alzheimer’s & Dementia.

Treatment with oral blarcamesine for older adults with Alzheimer’s disease led to significant slowing of clinical decline compared with placebo at 48 weeks, according to new research presented at CTAD.

Adults aged 50 years and older, particularly women, who experienced obstructive sleep apnea appeared to be at higher risk for dementia, according to a new study published in SLEEP Advances.

A clinical diagnostics company and biotech firm have announced a partnership to develop a blood-based tau pathology test that would assist in the diagnosis of Alzheimer’s disease.

In a cohort of community-dwelling older adults, poor sleep quality was indicative of incident motoric cognitive risk syndrome as well as increased physical and mental disability, according to research published in Neurology.

Poor sleep patterns in early midlife appeared to be associated with advanced brain age in late midlife, suggesting the importance of early sleep interventions to preserve brain health, according to study results.

Plasma pTau181 in combination with ApoE4 assays registered a high degree of accuracy in ruling out patients with a low probability of amyloid pathology in the early stages of Alzheimer’s disease, according to a poster presentation at CTAD.

The International Working Group has updated diagnostic guidelines for Alzheimer’s disease to include individuals with normal cognition who test positive for core biomarkers indicative of disease pathology.